Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.
- 15 July 2000
- journal article
- clinical trial
- Published by Physicians Postgraduate Press, Inc in The Journal of Clinical Psychiatry
- Vol. 61 (7) , 514-517
- https://doi.org/10.4088/jcp.v61n0709
Abstract
Adding the atypical neuroleptic risperidone to a serotonin reuptake inhibitor (SRI) has benefited patients with treatment-refractory obsessive-compulsive disorder (OCD). Since olanzapine and risperidone have similar serotonergic and dopaminergic receptor binding profiles, we tested the hypothesis that olanzapine augmentation would be beneficial in treatment-unresponsive OCD.Keywords
This publication has 0 references indexed in Scilit: